The latest MedTech deals signal investor confidence in a variety of technologies, including minimally invasive diagnostics, digital insulin platforms, neuromodulation solutions, and strategic portfolio initiatives. All these are pushing innovations from development into tangible clinical impact – get the full details in our funding tracker.
Solventum completes $4.1B sale of Purification & Filtration business to Thermo Fisher
Solventum announced that it completed the sale of its Purification & Fultration (P&F) business to Thermo Fisher Scientific. The company agreed to sell the business to Thermo Fisher for $4.1 billion in February.
It expects net proceeds of $3.4 billion from the deal and plans to use those proceeds primarily to pay down outstanding debt, as outlined in recent tender offers.
CEO Bryan Hanson
Last week’s tracker: Terumo, Tempus AI, and more
Galvanize Therapeutics closes $100m Series C financing, hires new CEO
Sofinnova Partners led the round. A global syndicate of investors also participated in the round. The company plans to use proceeds to expand its commercial footprint. It also hopes to advance its clinical and development activities related to Aliya and RheOx.
Doug Godshall now takes over as CEO of Galvanize as Dr. Jonathan Waldstreicher transitions to the role of president and chief strategy officer. Godshall originally joined the company’s board as its chair in 2021.
Chair and CEO Doug Godshall
ViCentra raises $85m to drive insulin pump’s US market entry
Dutch device company ViCentra has raised $85m to boost its Kaleido insulin patch pump’s entry onto the US market. The funding round was led by new investor Innovation Industries. Existing investors Partners in Equity, Invest-NL, and EQT Life Sciences and Health Innovations also participated.
The funding will therefore also support the scale-up of ViCentra’s manufacturing capabilities to meet this demand, along with filing activities with the US Food and Drug Administration (FDA) to support Kaleido’s US market entry.
CEO Tom Arnold
Cyted raises $44m to propel US market expansion of its endoscopic capsule
UK-based Cyted Health has raised $44m to accelerate the ongoing market adoption of its EndoSign device in the US. The gastrointestinal (GI) diagnostic company’s EndoSign is a swallowable ‘capsule sponge’.
the investment will help consolidate its position in the US market by expanding its presence and adding further innovations to its diagnostics portfolio.
CEO Marcel Gehrung
Boomerang Medical raises $20M for sacral neuromod tech for inflammatory bowel disease
Boomerang Medical announced that it raised $20 million in a Series B financing to support its implantable neuromodulation system. The women-led bioelectronic medicine company develops its technology to treat inflammatory bowel disease (IBD).
Arboretum Ventures and Hatteras Venture Partners led the financing. The company expects to use proceeds to advance BOOM-IBD2, its pivotal trial with an initial focus on ulcerative colitis.
CEO Heather Simonsen
SynCardia parent prices $17M IPO to support next-gen artificial heart
Picard Medical, the company behind the SynCardia Total Artificial Heart (TAH), announced the pricing of a $17 million initial public offering (IPO). The Tucson, Arizona–based company plans to offer 4.25 million shares of common stock priced at $4 apiece.
That equals proceeds of $17 million before deducting underwriting discounts and offering expenses. Underwriters have a 30-day option to purchase up to an additional 637,500 shares as well.
CEO Patrick NJ Schnegelsberg
Reveal HealthTech raises $7.2M to push AI deeper into US healthcare
Reveal HealthTech, a two-year-old startup specialising in AI solutions for healthcare, has raised $7.2 million in a Series A round led by Leo Capital, with participation from Sanos Capital.
The funding was described as pivotal for scaling. It also brings Reveal into the Cipher Collective, a network of AI-driven healthtech firms collaborating on care delivery transformation.
Founder and CEO Sanchit Mullick
Berlin Heals Holding raises over $5m to advance heart failure treatment
After completing a successful A1 fundraising round earlier this year, the company was able to advance testing and development of this new approach and initiate a new First-In-Man study called the CMIC-III trial.
This new A2 funding round will support the completion of this study, preparation for future double blinding studies and further testing and documentation for an eventual FDA Investigational Device Exemption study submission.
CEO John Brumfield
